ArticleAnnals of surgical oncology2026
Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Impact and Outcomes of Neoadjuvant Systemic Therapy for Invasive Lobular Carcinoma.Annals of surgical oncology · 2026Article
- Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report.Clinical case reports · 2026Article
- Axillary surgical de-escalation after neoadjuvant therapy in breast cancer: current evidence, clinical controversies, and future directions.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDe-escalation of axillary surgery for hormone receptor-positive breast cancer has gained traction, but guidelines for axillary management after neoadjuvant endocrine therapy (NET) remain ill-defined.
methodsFemale patients age ≥50 years with clinical T1-4c, N0-1, ER+/HER2-<PUB4> breast cancer (2012-2021) were selected from the National Cancer Database (NCDB) and divided into three groups based on treatment: upfront surgery, neoadjuvant chemotherapy (NAC), or NET. Axillary surgery was categorized as no axillary surgery, sentinel lymph node biopsy (SLNB) alone, sentinel lymph node biopsy followed by axillary lymph node dissection (ALND), or ALND alone. Descriptive analysis and logistic regression were used to identify factors associated with ALND, and survival analysis was performed.
resultsThe inclusion criteria were met by 792,581 patients. The majority underwent surgery first (94.3 %), whereas 2.6 % received NAC and 3.1 % received NET. After adjustment, the odds of undergoing ALND were shown to be higher for those receiving NAC (odds ratio [OR], 1.18; 95 % confidence interval [CI], 1.12-1.24) or NET (OR, 1.10; 95 % CI, 1.05-1.14) than for those receiving surgery first (p < 0.001). The patients receiving NET were less likely to convert from cN+ to ypN0 (8.3 % vs NAC 19.6 %; p < 0.001), but they still were less likely to undergo ALND after SLNB. Overall survival was highest among the patients in the surgery-first group regardless of clinical nodal status (p < 0.001).
conclusionsAlthough the patients receiving NET had lower rates of nodal pathologic complete response, this did not translate to higher conversion to ALND after SLNB, suggesting that providers do not interpret residual nodal disease after NET the same way as after NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.